Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

52.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials. 
Via Benzinga
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts
 
Via Benzinga
Why Exact Sciences (EXAS) Shares Are Trading Lower Today
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened... 
Via StockStory
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session. 
Via Benzinga
Earnings Scheduled For February 19, 2025
 
Via Benzinga
Forecasting The Future: 19 Analyst Projections For Exact Sciences
 
Via Benzinga
Exact Sciences (EXAS) Q4 2024 Earnings Call Transcript
EXAS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exact Sciences Stock Slides On Q4 Earnings: The Details
Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here's a look at the key details from the quarter. 
Via Benzinga
Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s... 
Via StockStory
Exact Sciences Announces Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Trump Calls For More Tariffs, Federal Reserve Minutes On Deck: What's Driving Markets Wednesday?
All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors. 
Via Benzinga
Topics Economy Government World Trade
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
From Exact Sciences Corp.
Via Business Wire
(EXAS) - Analyzing Exact Sciences's Short Interest
 
Via Benzinga
What 19 Analyst Ratings Have To Say About Exact Sciences
 
Via Benzinga
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
From Exact Sciences Corp.
Via Business Wire
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
The company is working to expand the uses and reimbursement for its blood-based tests for cancer. 
Via Investor's Business Daily
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?'
The company is facing numerous headline risks. But not all of them are legitimate, says one analyst. 
Via Investor's Business Daily
2 Healthcare Stocks to Buy Hand Over Fist in January
Via The Motley Fool
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are set for 2025 launch. 
Via Benzinga
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
From Exact Sciences Corp.
Via Business Wire
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP. 
Via Benzinga
Why Is Exact Sciences Stock Trading Higher On Monday?
Centers for Medicare & Medicaid Services finalizes 2025 pricing for Exact Sciences' Cologuard Plus, raising Medicare reimbursement by 16% and boosting growth projections for next year. 
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks
U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.'s largest trading partners - Canada and Mexico - with... 
Via Benzinga
Topics Government
Exact Sciences to Participate in December Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
From Exact Sciences Corp.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.